# Trading Journal

Agent reasoning log — appended on every routine run.

---

*Initialized — agent ready for first run.*

---

## 2026-04-29 — End-of-Day Summary

### Account Snapshot (post-close)
- Equity: $100,000.00
- Cash: $100,000.00
- Last equity (prior close): $100,000.00
- Daily P&L: $0.00 (0.00%)
- Long market value: $0.00
- Open positions: 0
- Open orders: 0 (none to cancel)

### Trades Today
None. The trade log shows no executions today. The watchlist is empty (no Pre-Market Research has populated HIGH-conviction candidates yet), so the Market Open Execution routine had nothing eligible to trade. No buy orders were placed and no positions were opened or closed.

What worked: discipline held — the agent did not force trades absent HIGH-conviction setups, which respects rule #7 (minimum confidence to trade).

What didn't: the upstream Pre-Market Research routine has not yet produced research output, so there were no candidates to act on. This is an input-side gap, not an execution-side error.

### Open Positions / Overnight Thesis
No overnight exposure. Portfolio is 100% cash. No event risk to monitor overnight.

### Self-Assessment — Rule Compliance
- Rule 1 (max 5% per position): N/A — no positions opened.
- Rule 2 (max 20% equity at risk): N/A — 0% deployed.
- Rule 3 (3% daily loss limit): respected — P&L is flat.
- Rule 4 (market hours only): N/A — no orders sent.
- Rule 5 (paper trading): respected — go_live.md not present, paper endpoint in use.
- Rule 6 (no leveraged ETFs / options / crypto): respected.
- Rule 7 (HIGH conviction only): respected — no trades on empty watchlist.
- Rule 8 (always set stop-loss): N/A — no entries.
No overrides taken.

### Strategy Adjustments for Tomorrow (2026-04-30)
1. Pre-Market Research must actually populate `memory/watchlist.md` with screened candidates and explicit conviction tags. Without that input, the execution routine is a no-op.
2. For Strategy 1 (Fibonacci Breakout): scan for S&P 500 / Nasdaq-100 names trading within 1–2% of a resistance level tested 3+ times, with rising 20-day volume.
3. For Strategy 2 (Small-Cap Biotech Dip Buy): scan FDA / ClinicalTrials.gov news for trial readouts and PDUFA outcomes from the last 1–3 sessions; flag any small-cap (≥$50M, ≤$2B) down 20–60% on efficacy (not safety) news.
4. Continue to require HIGH conviction for entry. No exceptions.
5. If watchlist remains empty tomorrow, log it as a research-pipeline failure, not a trading decision.

### Notification Status
Daily recap email send failed with "Connection timeout" reaching Gmail SMTP. This appears to be an environment-level egress issue, not a script bug (the helper validated env vars and proceeded to the SMTP step). Recap content is preserved in this journal entry. Worth confirming GMAIL_USER / GMAIL_APP_PASSWORD / network egress on next run.

